Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term guanfacine prolonged-release versus atomoxetine/placebo in children and adolescents with ADHD
NL-OMON55836Phase 4Recruiting
- Sponsor
- Takeda
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of guanfacine in attention deficit hyperactivity disorder (ADHD) (4 arms), sponsored by Takeda. Primary endpoint: Change from baseline in CANTAB Reaction Time task. Started Jan 2020; status: recruiting.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NL-OMON55836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55836.